Hypha Labs (FUNI) 10-K 17 Jan 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2022	Jan. 13, 2023	Mar. 31, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	DIGIPATH, INC.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron Street
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 1,585,804
Entity Common Stock, Shares Outstanding		75,146,820
Documents Incorporated by Reference [Text Block]	None
Auditor Firm ID	2738
Auditor Name	M&K CPAS, PLLC
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Current assets:
Cash	$ 56,168	$ 295,932
Accounts receivable, net	335,085	214,900
Deposits	25,141	24,751
Note receivable	100,000	230,929
Other current assets	45,710	60,353
Total current assets	562,104	826,865
Right-of-use asset	316,961	413,884
Fixed assets, net	460,823	647,252
Total non-current assets	777,784	1,061,136
Total Assets	1,339,888	1,888,001
Current liabilities:
Accounts payable	550,467	370,977
Accrued expenses	378,368	220,002
Current portion of operating lease liabilities	100,685	93,601
Current portion of finance lease liabilities		20,379
Current maturities of notes payable	725,920	259,425
Current maturities of convertible notes payable, net of discounts of $19,766 and $0 at September 30, 2022 and 2021, respectively	1,198,469	1,050,000
Total current liabilities	2,953,909	2,014,384
Non-current liabilities:
Operating lease liabilities	229,825	330,151
Notes payable	80,428	339,516
Convertible notes payable, net of discounts of $65,001 and $98,188 at September 30, 2022 and 2021, respectively	484,998	257,282
Total non-current liabilities	795,251	926,949
Total Liabilities	3,749,160	2,941,333
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 and 0 shares issued and outstanding as of September 30, 2022 and 2021 respectively	333,600
Stockholders’ Equity (Deficit):
Common stock, $0.001 par value, 250,000,000 shares authorized; 75,146,820 and 71,230,153 shares issued and outstanding at September 30, 2022 and 2021, respectively	75,147	71,230
Common stock Payable	71,745
Additional paid-in capital	17,117,958	16,825,765
Accumulated deficit	(20,008,771)	(17,951,653)
Total Stockholders’ Equity (Deficit)	(2,742,872)	(1,053,332)
Total Liabilities and Stockholders’ Equity (Deficit)	1,339,888	1,888,001
Series A Convertible Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock	1,048	1,326
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity (Deficit):
Preferred stock	$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Debt instrument, unamortized discount, current	$ 19,766	$ 0
Debt instrument, unamortized discount, noncurrent	$ 65,001	$ 98,188
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	75,146,820	71,230,153
Common stock, shares outstanding	75,146,820	71,230,153
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	0
Temporary equity, shares outstanding	333,600	0
Series A Convertible Preferred Stock [Member]
Series C convertible preferred stock, par value	$ 0.001	$ 0.001
Series C convertible preferred stock, shares authorized	10,000,000	10,000,000
Series C convertible preferred stock, shares issued	1,047,942	1,325,942
Series C convertible preferred stock, shares outstanding	1,047,942	1,325,942
Series C Convertible Preferred Stock [Member]
Series C convertible preferred stock, par value	$ 0.001	$ 0.001
Series C convertible preferred stock, shares authorized	1,000	1,000
Series C convertible preferred stock, shares issued	1,000	0
Series C convertible preferred stock, shares outstanding	1,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 2,699,920	$ 2,503,800
Cost of sales	1,633,972	1,788,635
Gross profit	1,065,948	715,165
Operating expenses:
General and administrative	1,359,005	934,143
Professional fees	656,860	581,635
Bad debts expense (recovery)	64,427	(28,165)
Total operating expenses	2,080,292	1,487,613
Operating loss	(1,014,344)	(772,448)
Other income (expense):
Interest expense	(260,274)	(144,957)
Interest income		929
Gain on settlement of debt		222,393
Other income		7,580
Credit loss	(782,500)
Total other income (expense)	(1,042,774)	85,945
Net loss	(2,057,118)	(686,503)
Preferred deemed dividend	(192,154)
Net loss to common shareholders	$ (2,249,272)	$ (686,503)
Net loss to common shareholders per share - basic and fully diluted	$ (0.03)	$ (0.01)
Weighted average number of common shares outstanding - basic and fully diluted	74,173,304	65,868,108

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series B Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Sep. 30, 2020		$ 1,326		$ 58,271		$ 16,116,400	$ (17,265,150)	$ (1,089,153)
Beginning balance, shares at Sep. 30, 2020		1,325,942		58,270,567
Common stock sold for cash				$ 900		19,350		20,250
Common stock sold for cash, shares				900,000
Common stock issued for debt conversion				$ 6,666		193,334		200,000
Common stock issued for debt conversion, shares				6,666,668
Common stock issued for services				$ 5,393		250,862		256,255
Common stock issued for services, shares				5,392,918
Stock-based compensation						147,631		147,631
Beneficial conversion feature on convertible notes payable						98,188		98,188
Net loss							(686,503)	(686,503)
Purchase of Series B Preferred shares, shares				6,666,668
Ending balance, value at Sep. 30, 2021		$ 1,326		$ 71,230		16,825,765	(17,951,653)	(1,053,332)
Ending balance, shares at Sep. 30, 2021		1,325,942		71,230,153
Common stock issued for services				$ 3,667		139,833		$ 143,500
Common stock issued for services, shares				3,666,667				3,666,667
Stock-based compensation						62,533		$ 62,533
Net loss							(2,057,118)	(2,057,118)
Purchase of Series B Preferred shares	$ 55,600
Purchase of Series B Preferred shares, shares	55,600
Conversion of Series A Preferred into Series B Preferred	$ 278,000	$ (278)				(85,568)		(85,846)
Conversion of Series A Preferred into Series B Preferred, shares	278,000	(278,000)
Issuance of Preferred C Shares			$ 1			360,299		360,300
Issuance of Preferred C Shares, shares			1,000
Common stock issued for settlement of accounts payable				$ 250		7,250		7,500
Common stock issued for settlement of accounts payable, shares				250,000
Common shares to be issued for debt discount					71,745			71,745
Deemed dividend on preferred exchange						(192,154)		(192,154)
Ending balance, value at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	$ 71,745	$ 17,117,958	$ (20,008,771)	$ (2,742,872)
Ending balance, shares at Sep. 30, 2022	333,600	1,047,942	1,000	75,146,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (2,057,118)	$ (686,503)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	64,427	(28,165)
Depreciation and amortization expense	204,151	292,133
Gain on settlement of debt		(222,393)
Credit loss	782,500
Stock-based compensation	566,233	403,886
Amortization of debt discounts	85,166	8,322
Decrease (increase) in assets:
Accounts receivable	(184,612)	55,410
Other current assets	5,821	(7,609)
Deposits	(390)	(6,076)
Right-of-use assets	96,923	91,822
Increase (decrease) in liabilities:
Accounts payable	186,989	(14,743)
Accrued expenses	158,366	62,679
Lease liabilities	(93,242)	(84,731)
Net cash (used) in operating activities	(184,786)	(135,968)
Cash flows from investing activities
Purchase of fixed assets	(17,722)	(56,206)
Advance of note receivable	(817,649)	(230,000)
Proceeds from sale of collateralized assets	175,000
Net cash (used) in investing activities	(660,371)	(286,206)
Cash flows from financing activities
Proceeds from short term advances		65,000
Repayments of short term advances		(30,112)
Principal payments on finance lease	(20,379)	(32,532)
Principal payments on note payable, equipment financing	(57,593)	(54,249)
Proceeds from notes payable	390,000	400,000
Repayments of notes payable	(125,000)
Proceeds from convertible notes	402,765	267,000
Repayments on convertible notes	(40,000)
Proceeds from sale of common stock		20,250
Proceeds from sale of preferred stock	55,600
Net cash provided by financing activities	605,393	635,357
Net increase (decrease) in cash	(239,764)	213,183
Cash - beginning	295,932	82,749
Cash - ending	56,168	295,932
Supplemental disclosures:
Interest paid	113,817	45,357
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of payables	7,500
Conversion of Series A preferred into Series B preferred	85,846
Subscription receivable for Series C preferred stock	100
Fixed assets transferred to settle accounts payable		2,226
Common stock issued for debt conversion		200,000
Transfer of notes payable and accrued interest into convertible notes payable		88,470
Stock payable issued for debt discounts on convertible notes payable	$ 71,745	$ 98,188

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and has plans to open labs in other states and countries that have legalized the sale of cannabis, beginning with California. Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 139,279 87,795 The Company had two customers representing 27% 10% 23% 27% 10% 29% Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations. Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 58,739 28,050 Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2022 and 2021, potential dilutive securities of 58,941,155 46,848,988 6,020,000 5,620,000 1,500,000 2,535,001 13,579,710 6,629,710 no Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity).

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $ 20,008,771 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2022 and 2021, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,138 $ - $ - Liabilities Lease liabilities - - 330,510 Notes payable - 806,348 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467 Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,957 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282 The fair value of our intellectual properties is deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2022 or 2021.

Note Receivable

Note Receivable	12 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Note Receivable	Note 4 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10% On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,056,570 . The loans bear interest at an annual rate of 8% . These loans are evidenced by secured demand notes, and are secured by a lien on the borrower’s assets and have a maturity date of August 23, 2022 . The Company has recorded interest income of $ 63,087 930 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent. The Company is currently in possession of equipment of C3 Labs, which it is in the process of liquidating. As of September 30, 2022, the Company had sold a portion of C3 Labs’ equipment for proceeds of $ 175,000 845,587 against the note receivable and related interest receivable . As of September 30, 2022, the net receivable balance is $ 100,000

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 5 – Fixed Assets Fixed assets consist of the following at September 30, 2022 and 2021: Schedule of Fixed Assets As of September 30, 2022 2021 Software $ 125,903 $ 125,903 Office equipment 71,601 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,455,479 1,453,716 Leasehold improvements 510,076 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,292,131 2,274,409 Less: accumulated depreciation (1,831,308 ) (1,627,157 ) Total $ 460,823 $ 647,252 On March 31, 2021, we distributed fixed assets with an aggregate net book value of $ 2,227 3,176 949 2,227 Depreciation and amortization expense totaled $ 204,151 292,133

Leases

Leases	12 Months Ended
	Sep. 30, 2022
Leases
Leases	Note 6 – Leases The Company leases its operating and office facility under a non-cancelable real property lease agreement that expires on August 31, 2025 The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Year Ended Year Ended September 30, September 30, 2022 2021 Operating lease cost $ 118,873 $ 118,873 Finance lease cost: Amortization of assets 19,839 19,839 Interest on lease liabilities 1,620 7,310 Total net lease cost $ 140,332 $ 146,022 Total net lease cost Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information September 30, September 30, 2022 2021 Operating leases: Operating lease assets $ 316,961 $ 413,884 Current portion of operating lease liabilities 100,685 $ 93,601 Noncurrent operating lease liabilities 229,825 330,151 Total operating lease liabilities $ 330,510 $ 423,752 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (59,516 ) (39,677 ) Equipment, net $ 39,677 $ 59,516 Current portion of finance lease liabilities $ - $ 20,379 Total finance lease liabilities $ - $ 20,379 Weighted average remaining lease term: Operating leases 2.92 3.92 Finance leases 0 0.55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 % Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the For the Year Ended Year Ended September 30, September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows provided by sublet operating leases $ - $ - Operating cash flows used for operating leases $ 93,601 $ 84,731 Financing cash flows used for finance leases $ 20,379 $ 32,532 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ - Total finance lease liabilities $ - $ - The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2021: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2023 $ 119,468 2024 123,543 2025 116,891 2026 - 2027 - Total future undiscounted lease payments 359,902 Less interest 29,392 Present value of lease payments 330,510 Less current portion 100,685 Long-term operating lease liabilities $ 229,825

Notes Payable

Notes Payable	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable Notes payable consists of the following at September 30, 2022 and 2021, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 400,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year term December 26, 2024 141,348 198,941 Total notes payable 806,348 598,941 Less: current maturities (725,920 ) (259,425 ) Notes payable $ 80,428 $ 339,516 The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 49,560 14,700

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable Convertible notes payable consist of the following at September 30, 2022 and 2021, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2022 2021 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 90,000 3,000,000 0.03 355,470 98,188 362,765 February 11, 2024 718,234 355,470 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 0.03 February 11, 2024 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 0.03 150,000 150,000 Total convertible notes payable 1,768,234 1,405,470 Less: unamortized debt discounts (84,767 ) (98,188 ) Total convertible debt 1,683,467 1,307,282 Less: current maturities 1,198,469 1,050,000 Convertible notes payable $ 484,998 $ 257,282 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 71,745 98,188 85,166 8,322 84,767 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 113,976 87,690 The Company recognized interest expense for the years ended September 30, 2022 and 2021, respectively, as follows: Schedule of Interest Expense September 30, 2022 September 30, 2021 Interest on short term loans $ - $ 1,558 Interest on capital leases 11,572 20,874 Interest on notes payable 49,560 11,302 Amortization of beneficial conversion features 85,166 8,322 Interest on convertible notes 113,976 102,901 Total interest expense $ 260,274 $ 144,957

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 9 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 1,000 Series A Preferred The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. During the year ended September 30, 2022, the Company offered to the Series A Preferred shareholders the ability to convert their Preferred A shares into Preferred B shares for an additional investment of 20% of their initial Series A investment 55,600 55,600 278,000 192,154 Series B Preferred The Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 4.99 Additional terms of the Series B Preferred include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet. On December 30, 2021, the Company entered into an Exchange Agreement with one of the Company’s institutional investors (the “Investor”), pursuant to which the Investor exchanged 278,000 278,000 55,600 1.00 55,600 Series C Preferred The Series C Preferred were designated on July 20, 2022. The principal feature of the Series C Preferred is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 0.10 On July 25, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Todd Denkin, the Company’s President, pursuant to which Mr. Denkin purchased 1,000 0.10 360,200 Common Stock Common stock consists of $ 0.001 250,000,000 75,146,820 Common Stock Transactions for the Year Ended September 30, 2022 During the year ended September 30, 2022, the Company issued 1,500,000 52,500 During the year ended September 30, 2022, the Company issued 2,166,667 91,000 During the year ended September 30, 2022, the Company issued 250,000 7,500 based on the closing price of the Company’s common stock on the dates of grant In connection with the Convertible Note extensions as described in Note 8, the Company was to issue, 7,150,000 71,745 based on the closing price of the Company’s common stock on the dates of grant Common Stock Transactions for the Year Ended September 30, 2021 On December 30, 2020, the Company sold 900,000 20,250 During the year ending September 30, 2021 the Company issued 5,392,918 256,255 2,744,585 1,898,333 750,000 During the year ending September 30, 2021 the Company issued 6,666,668 200,000 Amortization of Stock-Based Compensation A total of $ 143,500 of stock-based compensation expense was recognized during the year ended September 30, 2022 as a result of the issuance of 3,666,667 shares of common stock, as amortized over the requisite service period. A total of $ 256,255 5,392,918

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 10 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 Common Stock Option Issuances During the year ended September 30, 2022, the Company issued to an unrelated third party, options to purchase 1,000,000 20,994 143 0.021 0.024 During the year ending September 30, 2021 the Company issued options to purchase 2,800,000 142,862 2 167 185 0.0463 0.0576 0.0481 0.06 1,000,000 1,800,000 Amortization of Stock-Based Compensation A total of $ 62,533 147,631 15,187 The following is a summary of information about the stock options outstanding at September 30, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 6,020,000 6.01 0.07 5,573,571 $ 0.07 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan September 30, September 30, 2022 2021 Average risk-free interest rates 1.21 % 0.88 % Average expected life (in years) 5.00 5.00 Volatility 143 % 156 % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2022 and September 30, 2021, there were no The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2022 was approximately $ 0.03 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2020 3,570,000 $ 0.11 Options issued 2,800,000 0.05 Options repurchased/expired (750,000 ) (0.10 ) Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 0.02 Options forfeited (600,000 ) (0.11 ) Balance, September 30, 2022 6,020,000 $ 0.07 Exercisable, September 30, 2022 5,573,571 $ 0.07 As of September 30, 2022, these options in the aggregate had no intrinsic value as the per share market price of $ 0.007 0.07

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2022
Common Stock Warrants
Common Stock Warrants	Note 11 – Common Stock Warrants Warrants to purchase a total of 1,500,000 During the year ended September 30, 2022, warrants to purchase an aggregate total of 1,035,001 0.26 During the year ended September 30, 2021, warrants to purchase an aggregate total of 1,739,268 0.25 The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2022 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 1,500,000 7.44 $ 0.10 1,500,000 $ 0.10 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2020 4,274,269 $ 0.20 Warrants granted - - Warrants expired (1,739,268 ) (0.25 ) Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (1,035,001 ) (0.26 ) Balance, September 30, 2022 1,500,000 $ 0.10 Exercisable, September 30, 2022 1,500,000 $ 0.10 As of September 30, 2022, these warrants in the aggregate had no intrinsic value as the per share market price of $ 0.007 0.10

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax	Note 13 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2022 and 2021, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2022, the Company had approximately $ 14,908,500 2031 The effective income tax rate for the years ended September 30, 2022 and 2021 consisted of the following: Schedule of Effective Income Tax Rate 2022 2021 September 30, 2022 2021 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2022 2021 September 30, 2022 2021 Deferred tax assets: Net operating loss carry forwards $ 3,130,800 $ 2,958,700 Net deferred tax assets before valuation allowance $ 3,130,800 $ 2,958,700 Less: Valuation allowance (3,130,800 ) (2,958,700 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2022 and 2021, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On October 1, 2022, the Company amended the outstanding convertible promissory notes dated September 30, 2021 to extend the maturity date of December 30, 2022 to February 11, 2024 4,621,105 0.0074 On October 1, 2022, the Company amended the outstanding convertible promissory notes dated November 18, 2018 to extend the maturity date of December 30, 2022 to February 11, 2024 4,550,000 0.0074 On October 1, 2022, the Company issued a convertible promissory note in exchange for various advances made to the Company in the aggregate amount of $ 362,765 February 11, 2024 8 4,715,945 0.0074 On December 5, 2022, the Company entered into an Asset Purchase Agreement in which the Company sold the remaining collateralized assets held under the C3 Labs note receivable for a total purchase price of the $ 900,000 275,000 10

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory and data analytics company focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and has plans to open labs in other states and countries that have legalized the sale of cannabis, beginning with California.
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $ 139,279 87,795 The Company had two customers representing 27% 10% 23% 27% 10% 29%
Notes Receivable	Notes Receivable Notes receivable are reported in our consolidated balance sheets at the outstanding principal balance, plus costs incurred to originate the loans, net of any unamortized premiums or discounts on purchased loans. We use the effective interest rate method to recognize finance income, which produces a constant periodic rate of return on the investment. Unearned income, discounts and premiums are amortized to finance income in our consolidated statements of operations using the effective interest rate method. Interest receivable related to the unpaid principal is recorded together with the outstanding balance in our consolidated balance sheets. Upon the prepayment of a note receivable, any prepayment penalties and unamortized loan origination, closing and commitment fees are recorded as part of finance income in our consolidated statements of operations.
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 - Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $ 58,739 28,050
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2022 and 2021, potential dilutive securities of 58,941,155 46,848,988 6,020,000 5,620,000 1,500,000 2,535,001 13,579,710 6,629,710 no
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity).

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.
Schedule of Estimated Useful Lives of Property, Plant and Equipment	Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Schedule of Estimated Useful Lives of Property, Plant and Equipment Software 3 Office equipment 5 Furniture and fixtures 5 Lab equipment 7 Leasehold improvements Term of lease

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2022 and 2021, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,138 $ - $ - Liabilities Lease liabilities - - 330,510 Notes payable - 806,348 - Convertible notes payable, net of discounts of $ 84,767 - - 1,683,467 Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,957 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2022 and 2021: Schedule of Fixed Assets As of September 30, 2022 2021 Software $ 125,903 $ 125,903 Office equipment 71,601 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,455,479 1,453,716 Leasehold improvements 510,076 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,292,131 2,274,409 Less: accumulated depreciation (1,831,308 ) (1,627,157 ) Total $ 460,823 $ 647,252

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2022
Leases
Schedule of Components of Lease Expense	The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Year Ended Year Ended September 30, September 30, 2022 2021 Operating lease cost $ 118,873 $ 118,873 Finance lease cost: Amortization of assets 19,839 19,839 Interest on lease liabilities 1,620 7,310 Total net lease cost $ 140,332 $ 146,022 Total net lease cost
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information September 30, September 30, 2022 2021 Operating leases: Operating lease assets $ 316,961 $ 413,884 Current portion of operating lease liabilities 100,685 $ 93,601 Noncurrent operating lease liabilities 229,825 330,151 Total operating lease liabilities $ 330,510 $ 423,752 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (59,516 ) (39,677 ) Equipment, net $ 39,677 $ 59,516 Current portion of finance lease liabilities $ - $ 20,379 Total finance lease liabilities $ - $ 20,379 Weighted average remaining lease term: Operating leases 2.92 3.92 Finance leases 0 0.55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 %
Schedule of Supplemental Cash Flow and Other Information	Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the For the Year Ended Year Ended September 30, September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows provided by sublet operating leases $ - $ - Operating cash flows used for operating leases $ 93,601 $ 84,731 Financing cash flows used for finance leases $ 20,379 $ 32,532 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ - Total finance lease liabilities $ - $ -
Schedule of Future Minimum Annual Lease Commitments Under Operating Leases	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of September 30, 2021: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2023 $ 119,468 2024 123,543 2025 116,891 2026 - 2027 - Total future undiscounted lease payments 359,902 Less interest 29,392 Present value of lease payments 330,510 Less current portion 100,685 Long-term operating lease liabilities $ 229,825

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at September 30, 2022 and 2021, respectively: Schedule of Notes Payable September 30, September 30, On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 400,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year term December 26, 2024 141,348 198,941 Total notes payable 806,348 598,941 Less: current maturities (725,920 ) (259,425 ) Notes payable $ 80,428 $ 339,516

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at September 30, 2022 and 2021, respectively: Schedule of Convertible Notes Payable September 30, September 30, 2022 2021 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 90,000 3,000,000 0.03 355,470 98,188 362,765 February 11, 2024 718,234 355,470 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 0.03 February 11, 2024 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 0.03 150,000 150,000 Total convertible notes payable 1,768,234 1,405,470 Less: unamortized debt discounts (84,767 ) (98,188 ) Total convertible debt 1,683,467 1,307,282 Less: current maturities 1,198,469 1,050,000 Convertible notes payable $ 484,998 $ 257,282
Schedule of Interest Expense	The Company recognized interest expense for the years ended September 30, 2022 and 2021, respectively, as follows: Schedule of Interest Expense September 30, 2022 September 30, 2021 Interest on short term loans $ - $ 1,558 Interest on capital leases 11,572 20,874 Interest on notes payable 49,560 11,302 Amortization of beneficial conversion features 85,166 8,322 Interest on convertible notes 113,976 102,901 Total interest expense $ 260,274 $ 144,957

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 6,020,000 6.01 0.07 5,573,571 $ 0.07
Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan September 30, September 30, 2022 2021 Average risk-free interest rates 1.21 % 0.88 % Average expected life (in years) 5.00 5.00 Volatility 143 % 156 %
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2020 3,570,000 $ 0.11 Options issued 2,800,000 0.05 Options repurchased/expired (750,000 ) (0.10 ) Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 0.02 Options forfeited (600,000 ) (0.11 ) Balance, September 30, 2022 6,020,000 $ 0.07 Exercisable, September 30, 2022 5,573,571 $ 0.07

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2022
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2022 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 1,500,000 7.44 $ 0.10 1,500,000 $ 0.10
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2020 4,274,269 $ 0.20 Warrants granted - - Warrants expired (1,739,268 ) (0.25 ) Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (1,035,001 ) (0.26 ) Balance, September 30, 2022 1,500,000 $ 0.10 Exercisable, September 30, 2022 1,500,000 $ 0.10

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	The effective income tax rate for the years ended September 30, 2022 and 2021 consisted of the following: Schedule of Effective Income Tax Rate 2022 2021 September 30, 2022 2021 Federal statutory income tax rate 21 % 21 % State income taxes - % - % Change in valuation allowance (21 )% (21 )% Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: Schedule of Deferred Tax Asset 2022 2021 September 30, 2022 2021 Deferred tax assets: Net operating loss carry forwards $ 3,130,800 $ 2,958,700 Net deferred tax assets before valuation allowance $ 3,130,800 $ 2,958,700 Less: Valuation allowance (3,130,800 ) (2,958,700 ) Net deferred tax assets $ - $ -

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	12 Months Ended
	Sep. 30, 2022
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc	[2]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd.	[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Sep. 30, 2022
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment estimated useful lives	Term of lease

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Product Information [Line Items]
Allowance for doubtful accounts	$ 139,279	$ 87,795
Advertising expense	$ 58,739	$ 28,050
Antidilutive securities earning per share	0	0
Conversion of preferred shares	8,340,000
Series A Convertible Preferred Stock [Member]
Product Information [Line Items]
Conversion of preferred shares	13,579,710
Series B Convertible Preferred Stock [Member]
Product Information [Line Items]
Conversion of preferred shares		6,629,710
Convertible Debt Securities [Member]
Product Information [Line Items]
Antidilutive securities earning per share	58,941,155	46,848,988
Share-Based Payment Arrangement, Option [Member]
Product Information [Line Items]
Antidilutive securities earning per share	6,020,000	5,620,000
Warrant [Member]
Product Information [Line Items]
Antidilutive securities earning per share	1,500,000	2,535,001
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk, percentage	27%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage		27%
Gross Revenue [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk, percentage		10%
Gross Revenue [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage	10%
Revenue [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk, percentage		29%
Revenue [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage	23%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 20,008,771	$ 17,951,653

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash	$ 56,138	$ 295,957
Lease liabilities
Note payable
Convertible notes payable, net of discounts
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities
Note payable	806,348	598,941
Convertible notes payable, net of discounts
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities	330,510	444,131
Note payable
Convertible notes payable, net of discounts	$ 1,683,467	$ 1,307,282

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Convertible notes discounts	$ 84,767	$ 98,188
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 84,767	$ 98,188

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	12 Months Ended		13 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Jun. 13, 2019
Defined Benefit Plan Disclosure [Line Items]
Interest Income (Expense), Net	$ 63,087	$ 930
Interest receivable	64,017		$ 64,017
Net receivables	100,000	$ 230,929	100,000
Northwest Analytical Labs, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party				$ 95,000
Note bearing interest rate				10%
C3 Labs, Inc., [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party	$ 1,056,570		$ 1,056,570
Note bearing interest rate	8%		8%
Debt Instrument, Maturity Date			Aug. 23, 2022
Proceeds from sale of equipment	$ 175,000
Financing Receivable, Allowance for Credit Loss, Current	845,587		$ 845,587
Net receivables	$ 100,000		$ 100,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Software	$ 125,903	$ 125,903
Office equipment	71,601	71,601
Furniture and fixtures	29,879	29,879
Lab equipment	1,455,479	1,453,716
Leasehold improvements	510,076	494,117
Lab equipment held under capital leases	99,193	99,193
Fixed assets, gross	2,292,131	2,274,409
Less: accumulated depreciation	(1,831,308)	(1,627,157)
Total	$ 460,823	$ 647,252

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Fixed assets		$ 460,823	$ 647,252
Accumulated depreciation		1,831,308	1,627,157
Depreciation and amortization expense		$ 204,151	$ 292,133
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets	$ 3,176
Chief Executive Officer [Member]
Property, Plant and Equipment [Line Items]
Fixed assets	2,227
Chief Executive Officer [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Accumulated depreciation	949
Loss of assets	$ 2,227

Schedule of Components of Lease

Schedule of Components of Lease Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases
Operating lease cost	$ 118,873	$ 118,873
Amortization of assets	19,839	19,839
Interest on lease liabilities	1,620	7,310
Total net lease cost	$ 140,332	$ 146,022

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Leases
Operating lease assets	$ 316,961	$ 413,884
Current portion of operating lease liabilities	100,685	93,601
Noncurrent operating lease liabilities	229,825	330,151
Total operating lease liabilities	330,510	423,752
Equipment, at cost	99,193	99,193
Accumulated amortization	(59,516)	(39,677)
Equipment, net	39,677	59,516
Current portion of finance lease liabilities		20,379
Total finance lease liabilities		$ 20,379
Weighted average remaining lease term operating leases	2 years 11 months 1 day	3 years 11 months 1 day
Weighted average remaining lease term Finance leases	0 years	6 months 18 days
Weighted average discount rate operating leases	5.75%	5.75%
Weighted average discount rate finance lease	18.41%	18.41%

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Leases
Operating cash flows provided by sublet operating leases
Operating cash flows used for operating leases	93,601	84,731
Financing cash flows used for finance leases	20,379	32,532
Total operating lease liabilities
Total finance lease liabilities

Schedule of Future Minimum Annu

Schedule of Future Minimum Annual Lease Commitments Under Operating Leases (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Leases
2023	$ 119,468
2024	123,543
2025	116,891
2026
2027
Total future undiscounted lease payments	359,902
Less interest	29,392
Present value of lease payments	330,510	$ 423,752
Less current portion	100,685	93,601
Long-term operating lease liabilities	$ 229,825	$ 330,151

Leases (Details Narrative)

Leases (Details Narrative)	12 Months Ended
	Sep. 30, 2022
Leases
Lease Expiration Date	Aug. 31, 2025

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Total notes payable	$ 806,348	$ 598,941
Less: current maturities	(725,920)	(259,425)
Notes payable	80,428	339,516
Notes payable one [Member]
Short-Term Debt [Line Items]
Total notes payable	665,000	400,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 141,348	$ 198,941

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Repayments of notes payable			$ 125,000
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 675,000
Debt instrument interest percentage	12%
Debt Instrument, Maturity Date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Debt conversion original debt amount			115,000
Repayments of notes payable			$ 125,000
Note Payable [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage		5.75%
Debt Instrument, Maturity Date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		five-year term

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,768,234	$ 1,405,470
Less: unamortized debt discounts	(84,767)	(98,188)
Total convertible debt	1,683,467	1,307,282
Less: current maturities	1,198,469	1,050,000
Convertible notes payable	484,998	257,282
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	718,234	355,470
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

1 Months Ended

12 Months Ended

Sep. 30, 2022

Aug. 11, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Feb. 10, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Aug. 18, 2022

Sep. 30, 2022

Sep. 30, 2021

Short-Term Debt [Line Items]

Convertible debt

$ 402,765

$ 267,000

Amortization of debt discount premium

85,166

$ 8,322

Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

9%

Debt principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Convertible debt

$ 10,000

Shares of common stock converted

333,334

Shares of common stock issued

650,000

Debt instrument fair value

$ 6,989

Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

9%

Debt principal amount

$ 50,000

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Convertible debt

$ 50,000

Shares of common stock converted

1,666,667

Shares of common stock issued

1,950,000

Debt instrument fair value

$ 20,968

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

9%

Debt principal amount

$ 50,000

$ 400,000

$ 350,000

Maturity date

Aug. 10, 2022

Feb. 11, 2024

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Convertible debt

$ 50,000

Shares of common stock converted

1,666,667

Shares of common stock issued

4,550,000

Debt instrument fair value

$ 43,788

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

8%

Debt principal amount

$ 90,000

$ 200,000

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Conversion price per share

$ 0.03

$ 0.11

Convertible debt

$ 362,765

Shares of common stock converted

3,000,000

Debt instrument maturity date description

On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share

Debt instrument periodic payment

$ 355,470

Amortization of debt discount premium

$ 98,188

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

8%

Debt principal amount

$ 350,000

Maturity date

Feb. 11, 2024

Aug. 10, 2022

Conversion price per share

$ 0.03

$ 0.14

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Debt instrument interest percentage

8%

Debt principal amount

$ 150,000

Maturity date

Aug. 10, 2022

Conversion price per share

$ 0.03

$ 0.14

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 49,560	$ 14,700

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Interest on short term loans		$ 1,558
Interest on capital leases	11,572	20,874
Interest on notes payable	49,560	11,302
Amortization of beneficial conversion features	85,166	8,322
Interest on convertible notes	113,976	102,901
Total interest expense	$ 260,274	$ 144,957

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Convertible notes discounts	$ 65,001	$ 98,188
Amortization of debt discounts	85,166	8,322
Unamortized discounts	$ 84,767	98,188
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 71,745	98,188
Amortization of debt discounts	85,166	8,322
Unamortized discounts	84,767	98,188
Convertible notes interest expense	$ 113,976	$ 87,690

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			12 Months Ended
	Jul. 25, 2022	Dec. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Class of Stock [Line Items]
Purchase price			100%
Proceeds from issuance of preference stock			$ 55,600
Number of shares converted			$ 192,154
Conversion of stock shares issued			8,340,000
Issued and outstanding common stock			4.99%
Common stock par value			$ 0.001	$ 0.001
Common stock authorized			250,000,000	250,000,000
Common stock, shares issued			75,146,820	71,230,153
Common stock, shares outstanding			75,146,820	71,230,153
Stock issued during period, shares, issued for services			3,666,667
Stock issued during period, value, issued for services			$ 143,500	$ 256,255
Stock issued during period value settlement			7,500
Issuance of common stock for compensation, shares				5,392,918
Third Party Consultants [Member]
Class of Stock [Line Items]
Number of shares issued				1,800,000
Officers [Member]
Class of Stock [Line Items]
Number of shares issued				2,744,585
Board of [Member]
Class of Stock [Line Items]
Number of shares issued				1,898,333
President [Member]
Class of Stock [Line Items]
Number of shares issued				750,000
Consultant [Member]
Class of Stock [Line Items]
Stock-based compensation expense			$ 143,500	$ 256,255
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued				6,666,668
Stock issued during period, shares, issued for services			3,666,667	5,392,918
Stock issued during period, value, issued for services			$ 3,667	$ 5,393
Stock issued during period value settlement			$ 250
Stock issued during period shares settlement			250,000
Sale of Common stock				900,000
Proceeds from sale of equity				$ 20,250
Debt instrument, face amount				$ 200,000
Common Stock [Member] | Chief Financial Officer [Member]
Class of Stock [Line Items]
Stock issued during period, shares, issued for services			1,500,000
Stock issued during period, value, issued for services			$ 52,500
Common Stock [Member] | Third Party Consultants [Member]
Class of Stock [Line Items]
Stock issued during period, shares, issued for services			2,166,667
Stock issued during period, value, issued for services			$ 91,000
Stock issued during period value settlement			$ 250,000
Stock issued during period shares settlement			7,500
Common Stock [Member] | Lenders [Member]
Class of Stock [Line Items]
Stock issued during period, shares, conversion of units			7,150,000
Stock payable fair value			71,745
Common Stock [Member] | Officers [Member]
Class of Stock [Line Items]
Number of shares issued				1,000,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares designated			$ 6,000,000
Preferred stock, shares issued			1,047,942	1,325,942
Preferred stock, shares outstanding			1,047,942	1,325,942
Conversion of stock shares issued			13,579,710
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated			$ 1,500,000
Conversion of stock shares issued				6,629,710
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000	1,000
Preferred stock, par value			$ 0.001	$ 0.001
Preferred stock, shares designated			$ 1,000
Preferred stock, shares designated remaining			2,499,000
Preferred stock, shares issued			1,000	0
Preferred stock, shares outstanding			1,000	0
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued			1,047,942
Preferred stock, shares outstanding			1,047,942
Conversion of stock shares converted			1,047,942
Number of shares converted			5,239,710
Common stock, conversion features			No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Conversion of stock description			the Company offered to the Series A Preferred shareholders the ability to convert their Preferred A shares into Preferred B shares for an additional investment of 20% of their initial Series A investment
Proceeds from issuance of preference stock			$ 55,600
Series A Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted		278,000
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership			4.99%
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value			$ 1
Preferred stock, shares issued			333,600
Preferred stock, shares outstanding			333,600
Conversion of stock shares converted			333,600
Number of shares converted			278,000
Conversion of stock description			Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends
Number of shares issued			55,600
Number of shares converted			$ 192,154
Preferred stock voting rights			$ 0.04
Series B Preferred Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Shares, purchased		55,600
Share weighted average price of shares purchased		$ 1
Gross proceeds		$ 55,600
Series B Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted		278,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued			1,000
Preferred stock, shares outstanding			1,000
Preferred stock voting rights			$ 0.10
Preferred stock voting rights			200,000
Series C Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted	1,000
Share weighted average price of shares purchased	$ 0.10
Compensation expenses to officer	$ 360,200

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.05
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	6,020,000
Weighted Average Remaining Contractual Life	6 years 3 days
Weighted Average Exercise Price	$ 0.07
Number of Shares Exercisable | shares	5,573,571
Weighted Average Exercise Price Exercisable	$ 0.07

Schedule of Weighted-Average As

Schedule of Weighted-Average Assumptions Used for Grants Under Fixed Option Plan (Details)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Average risk-free interest rates	1.21%	0.88%
Average expected life (in years)	5 years	5 years
Volatility	143%	156%

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details) - $ / shares	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Ending balance	5,620,000	3,570,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.08	$ 0.11
Number of Shares Options issued	1,000,000	2,800,000
Weighted Average Exercise Price, Options issued	$ 0.02	$ 0.05
Number of Shares Options repurchased/expired		(750,000)
Weighted Average Exercise Price, Options repurchased/expired		$ (0.10)
Number of Shares Options forfeited	(600,000)
Weighted Average Exercise Price, Options Forfeited	$ (0.11)
Number of Shares Outstanding, Ending balance	6,020,000	5,620,000
Weighted Average Exercise Price, Outstanding, Ending	$ 0.07	$ 0.08
Number of Shares Exercisable	5,573,571
Weighted Average Exercise Price, Exercisable	$ 0.07

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		12 Months Ended
	Jun. 21, 2016	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted to purchase shares of common stock		1,000,000	2,800,000
Stock issued during period, value, issued for services		$ 143,500	$ 256,255
Stock option, volatility rate		143%	156%
Options exercise price per share		$ 0.02	$ 0.05
Stock option, minimum volatility rate			167%
Stock option, maximum volatility rate			185%
Weighted average exercise price per share			$ 0.10
Intrinsic value, market price per share		0.007
Intrinsic value weighted-average exercise price per share		$ 0.07
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 62,533	$ 147,631
Unamortized expenses expected to be expensed		15,187
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period, value, issued for services		$ 3,667	$ 5,393
Number of shares issued			6,666,668
Weighted average exercise price per share		$ 0	$ 0
Unrelated Third Party [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option, volatility rate		143%
Stock option, call option per share		$ 0.021
Options exercise price per share		$ 0.024
Officers [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			2,744,585
Officers [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			1,000,000
Third Party Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued			1,800,000
Third Party Consultants [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period, value, issued for services		$ 91,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted to purchase shares of common stock			2,800,000
Stock issued during period, value, issued for services			$ 142,862
Options exercise price per share		$ 0.03
Stock remaining options vesting period			2 years
Equity Option [Member] | Unrelated Third Party [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted to purchase shares of common stock		1,000,000
Stock issued during period, value, issued for services		$ 20,994
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option, call option per share				$ 0.0576
Options exercise price per share				0.06
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option, call option per share				0.0463
Options exercise price per share				$ 0.0481
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	12 Months Ended
	Sep. 30, 2022 $ / shares shares
Common Stock Warrants
Range of Exercise Price, Minimum	$ 0.10
Number of Warrants Outstanding | shares	1,500,000
Weighted Average Remaining Contractual Life	7 years 5 months 8 days
Weighted Average Exercise Price	$ 0.10
Number of Warrants Exercisable | shares	1,500,000
Weighted Average Exercise Price, Exercisable	$ 0.10

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Common Stock Warrants
Number of Shares, Balance beginning	2,535,001	4,274,269
Weighted Average Exercise Price, Balance beginning	$ 0.17	$ 0.20
Number of Shares, Warrants granted
Weighted Average Exercise Price, Warrants granted
Number of Shares, Warrants expired	(1,035,001)	(1,739,268)
Weighted Average Exercise Price, Warrants expired	$ (0.26)	$ (0.25)
Number of Shares, Balance ending	1,500,000	2,535,001
Weighted Average Exercise Price, Balance, ending	$ 0.10	$ 0.17
Number of Shares, Exercisable	1,500,000
Weighted Average Exercise Price, Exercisable	$ 0.10

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - $ / shares	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Number of warrant to purchase of common stock shares	1,500,000
Intrinsic value, market price per share	$ 0.007
Intrinsic value weighted-average exercise price per share	$ 0.07
Warrant [Member]
Number of warrant to purchase of common stock shares	1,035,001	1,739,268
Weighted average exercise price	$ 0.26	$ 0.25
Intrinsic value, market price per share	0.007
Intrinsic value weighted-average exercise price per share	$ 0.10

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21%	21%
State income taxes
Change in valuation allowance	(21.00%)	(21.00%)
Net effective income tax rate

Schedule of Deferred Tax Asset

Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 3,130,800	$ 2,958,700
Net deferred tax assets before valuation allowance	3,130,800	2,958,700
Less: Valuation allowance	(3,130,800)	(2,958,700)
Net deferred tax assets

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2022 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 14,908,500
Operating loss expiration	2031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		12 Months Ended
	Oct. 01, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Number of warrant to purchase of common stock shares		1,500,000
Convertible debt		$ 402,765	$ 267,000
Purchase price down payment		$ 100,000	$ 230,929
Subsequent Event [Member] | Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Debt instrument stated percentage	10%
Purchase price note receivable	$ 900,000
Purchase price down payment	$ 275,000
Convertible Note One [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument maturity date	Feb. 11, 2024
Number of warrant to purchase of common stock shares	4,621,105
Warrants exercise price per share	$ 0.0074
Convertible Note Two [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument maturity date	Feb. 11, 2024
Number of warrant to purchase of common stock shares	4,550,000
Warrants exercise price per share	$ 0.0074
Convertible Note Three [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument maturity date	Feb. 11, 2024
Number of warrant to purchase of common stock shares	4,715,945
Warrants exercise price per share	$ 0.0074
Convertible debt	$ 362,765
Debt instrument stated percentage	8%